Publication Name	World Journal of Psychiatry
Manuscript ID	64875
Country	Germany

Received	2021-02-24 16:39
Peer-Review Started	2021-02-24 16:42
To Make the First Decision
Return for Revision	2021-04-21 00:12
Revised	2021-06-06 17:22
Second Decision	2021-08-04 03:34
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-08-04 08:13
Articles in Press	2021-08-04 08:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-09-10 15:05
Publish the Manuscript Online	2021-09-15 10:23

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Minireviews
Article Title	Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
Manuscript Source	Invited Manuscript
All Author List	Michael Soyka and Andreas Guenter Franke
ORCID	Author(s) ORCID Number Michael Soyka http://orcid.org/0000-0002-8271-9151 Andreas Guenter Franke http://orcid.org/0000-0002-7504-9015
Funding Agency and Grant Number
Corresponding Author	Michael Soyka, MD, Professor, Psychiatric Hospital, University of Munich, Nußbaumstr 7, München 80336, Germany. michael.soyka@outlook.de
Key Words	Opioids; Opioid dependence; Maintenance treatment; Methadone; Buprenorphine; Depot; Implant
Core Tip	Although opioid maintenance therapy with methadone or buprenorphine is the widely accepted first line treatment in opioid use disorders (OUDs) the risk of diversion and low retention rates limit its use. While previous attempts to introduce long-acting methadone analogues have failed due to cardiac side effects in recent years, three different long-acting buprenorphine formulations have been developed and successfully studied in opioid users, two weekly or monthly depot injections (CAM 2038, RBP-6000) and one implant (probuphine). The prospects of these new medications are significant by optimizing retention and compliance and minimizing the risk of diversion. Thus these novel medications can facilitate treatment of OUDs significantly.
Publish Date	2021-09-15 10:23
Citation	Soyka M, Franke AG. Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations. World J Psychiatr 2021; 11(9): 543-552
URL	https://www.wjgnet.com/2220-3206/full/v11/i9/543.htm
DOI	https://dx.doi.org/10.5498/wjp.v11.i9.543

Full Article (PDF)	WJP-11-543.pdf
Full Article (Word)	WJP-11-543.docx
Manuscript File	64875_Auto_Edited-JPY.docx
Answering Reviewers	64875-Answering reviewers.pdf
Audio Core Tip	64875-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	64875-Conflict-of-interest statement.pdf
Copyright License Agreement	64875-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	64875-Language certificate.pdf
Peer-review Report	64875-Peer-review(s).pdf
Scientific Misconduct Check	64875-Bing-Wang JL-1.jpg
Scientific Misconduct Check	64875-Bing-Fan JR-2.png
Scientific Misconduct Check	64875-Scientific misconduct check.pdf
Scientific Editor Work List	64875-Scientific editor work list.pdf
CrossCheck Report	64875-CrossCheck report.pdf
CrossCheck Report	64875-CrossCheck.png